Our key moments
-
2018
-
TEOXANE
15 year anniversary of TEOXANE: a tribute to enduring excellence
Establishment of a new subsidiary in Poland
-
-
2017
-
TEOSYAL® RHA
9 million TEOSYAL® dermal filler injections*
5th subsidiary in Spain after Germany, France, Italy and UK
-
-
2017
-
TEOSYAL® RHA
Opening of a second production line. FDA approval for RHA®2, RHA®3, RHA®4 for the correction of moderate to severe dynamic facial wrinkles and folds
New packagings for HA range and new names for Redensity 1 & 2
-
-
2016
-
TEOSYAL® RHA
New cosmeceutics with RHA® technology: a serum with Vitamin C, and a hydrogel mask
-
-
2015
-
TEOSYAL® RHA
Launch of the Resilient Hyaluronic Acid gel line: TEOSYAL®RHA for Dynamic Aesthetics. A novel cross-linking technology that adapts to the movements and dynamism of the face
-
-
2015
-
SKINCARE
Cosmeceutics innovations: eye-contour and anti-ageing SPF protection
-
-
2015
-
TEOSYAL® PEN
The 1st motorised, cordless hyaluronic acid injection system - more precise injections for practitioners coupled with reduced pain for patients
-
-
2014
-
TEOSYAL®
5 million TEOSYAL® injections
-
-
2014
-
TEOSYAL® RHA
Integration of RHA resilient hyaluronic acid® , novel cross-linking HA technology, in the newly created TEOXANE Cosmeceuticals line
-
-
2013
-
10 year anniversary of TEOXANE
Celebrating a decade of innovation, independence and the pursuit of excellence
-
-
2012
-
TEOSYAL® RHA
2 groundbreaking launches that changed anti-ageing approaches: a dermal filler, Redensity 2, specifically designed as an under- eye circle fighter and a cocktail of free HA and nutriments, Redensity 1, renown worldwide as a unique beauty booster
-
-
2011
-
TEOXANE
TEOXANE is the 3rd manufacturer to master the addition of lidocaine in dermal fillers, creating the TEOSYAL® PureSense range, for a more comfortable injection experience
-
-
2009
-
TEOSYAL®
Creation of TEOSYAL® Cosmeceuticals range – A perfect complement to facial aesthetic procedures
-
-
2006
-
TEOSYAL®
Ultra Deep, 1st volumiser by injection (fine needle)
-
-
2004
-
TEOSYAL® Classic range
A state-of-the art range of hyaluronic acid-based dermal fillers that allows practitioners to address the main rejuvenation concerns
-
-
2003
-
TEOXANE
Creation of TEOXANE Laboratories in Geneva, Switzerland
-
References
* RHA 2, RHA 3 and RHA 4 are trademarks of TEOXANE SA. They are class III medical devices and have received FDA approval but are not yet commercialized in the United States. The United States Federal law restricts this device to sale by or on the order of a physician or license practitioner. RHA 2, RHA 3 and RHA 4 are indicated for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. RHA 2, RHA 3, and RHA 4 are sterile gels containing crosslinked hyaluronic acid in physiological buffer and 0.3% lidocaine hydrochloride to reduce pain on injection. RHA 2, RHA 3, RHA 4 are contraindicated in patients with previous hypersensitivity to local anaesthetics of the amide type, such as lidocaine. Please refer to the Instructions for Use (https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170002C.pdf). It is the practitioner’s full responsibility to read and inform the patient about contraindications, warnings, precautions, risks and benefits.
